Q2 FY2026 · ended Jun 30, 2026 · Revenue $243,745, +49.0% YoY · Filed Aug 11, 2026
Coya Therapeutics, Inc. (COYA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $243,745 and a net loss of $6.6 million.
Revenue
$243,745
+49.0% vs year-ago quarter
Net income
$-6.64M
-8.9% vs year-ago quarter
Operating cash flow
$-7.38M
-27.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.28
+22.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
23.46M
+40.3% vs year-ago quarter
Net cash
—
Operating margin
-288.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $243,745 | $251,147 | $4.0M | $3.6M | $163,616 |
| Operating income | -$7.0M | -$7.6M | -$6.0M | -$2.4M | -$6.4M |
| Net income | -$6.6M | -$7.2M | -$5.7M | -$2.1M | -$6.1M |
| Diluted EPS | -$0.28 | -$0.32 | -$0.34 | -$0.13 | -$0.36 |
| Operating cash flow | -$7.4M | -$6.2M | -$1.0M | -$1.1M | -$5.8M |
| Total assets | $47.3M | $53.3M | $50.0M | $32.0M | $33.5M |
| Total liabilities | $4.0M | $4.3M | $6.9M | $4.8M | $5.1M |
| Stockholders' equity | $43.3M | $49.0M | $43.0M | $27.3M | $28.3M |
| Cash and investments | $43.2M | $50.7M | $46.8M | $28.1M | $29.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 7, 2026 | Mar 29, 2026 |
All 230 Coya Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.